3378 — Hanx Biopharmaceuticals (Wuhan) Co Balance Sheet
0.000.00%
Last trade - 00:00- HK$2.32bn
- HK$2.48bn
Annual balance sheet for Hanx Biopharmaceuticals (Wuhan) Co, fiscal year end - December 31st, CNY millions except per share, conversion factor applied.
2023 December 31st | 2024 December 31st | |
|---|---|---|
| Period Length: | — | — |
| Source: | PROSPECTUS | PROSPECTUS |
| Standards: | IFRS | IFRS |
| Status: | Final | Final |
| Cash and Equivalents | ||
| Short Term Investments | ||
| Cash and Short Term Investments | 204 | 174 |
| Prepaid Expenses | ||
| Total Other Current Assets | ||
| Total Current Assets | 299 | 243 |
| Gross Property, Plant And Equipment | ||
| Accumulated Depreciation | ||
| Net Property, Plant And Equipment | 24 | 24.1 |
| Net Intangible Assets | ||
| Long Term Investments | ||
| Other Long Term Assets | ||
| Total Assets | 586 | 501 |
| Accounts Payable | ||
| Accrued Expenses | ||
| Notes Payable / Short Term Debt | ||
| Current Portion of Long Term Debt / Capital Leases | ||
| Total Other Current Liabilities | ||
| Total Current Liabilities | 62.9 | 197 |
| Long Term Debt | ||
| Capital Lease Obligations | ||
| Total Long Term Debt | ||
| Total Debt | ||
| Deferred Income Tax | ||
| Minority Interest | ||
| Total Liabilities | 318 | 335 |
| Common Stock | ||
| Retained Earnings (Accumulated Deficit) | ||
| Other Equity | ||
| Total Equity | 268 | 166 |
| Total Liabilities & Shareholders' Equity | 586 | 501 |
| Total Common Shares Outstanding |